FMP

FMP

Enter

IDXX - IDEXX Laboratories, ...

photo-url-https://images.financialmodelingprep.com/symbol/IDXX.png

IDEXX Laboratories, Inc.

IDXX

NASDAQ

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

433.25 USD

5.92 (1.37%)

Latest IDXX News

Seeking Alpha

Aug 11, 2024

IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits

IDEXX reported lower full-year organic revenue growth due to reduced U.S. clinical visits. Weak consumer sentiment and ongoing staffing challenges may continue to impact clinical visits in the near future. Launch of new menu expansion for Catalyst platform may drive growth in diagnostic business, but the stock remains overvalued.

Read More

Seeking Alpha

Aug 6, 2024

IDEXX Laboratories, Inc. (IDXX) Q2 2024 Earnings Call Transcript

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Chris Schott - JPMorgan Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jonathan Block - Stifel David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Second Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being record...

Read More

Zacks Investment Research

Aug 6, 2024

IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down

IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.

Read More

Zacks Investment Research

Aug 6, 2024

Idexx (IDXX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More

Zacks Investment Research

Aug 6, 2024

Idexx Laboratories (IDXX) Lags Q2 Earnings Estimates

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.44 per share, missing the Zacks Consensus Estimate of $2.87 per share. This compares to earnings of $2.67 per share a year ago.

Read More

Zacks Investment Research

Aug 6, 2024

The Zacks Analyst Blog Baxter International, Henry Schein and IDEXX Laboratories

Baxter International, Henry Schein and IDEXX Laboratories are included in this Analyst Blog.

Read More

Seeking Alpha

Aug 6, 2024

The Final Peak Week Of The Q2 Season Begins Amid Souring Economic Data

This marks the last peak week of the Q2 earnings season with 3,908 companies expected to report. Earnings have come in better-than-expected, but tend to be overshadowed by economic data. Outlier earnings this week include: CSX, CAT, and VFC.

Read More

Zacks Investment Research

Aug 5, 2024

What's in Store for These 3 MedTech Stocks in Q2 Earnings?

MedTech companies' quarterly results are likely to be strong on a sequential basis. Let's see how BAX, HSIC and IDXX are placed ahead of their earnings releases.

Read More

Zacks Investment Research

Aug 1, 2024

Unlocking Q2 Potential of Idexx (IDXX): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

Read More

Zacks Investment Research

Jul 22, 2024

Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings

IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep